GoodRx Holdings (GDRX) Stock Price Target 2026

The average analyst price target for GoodRx Holdings is $5.79, 64.0% above the current price. Of 15 analysts, 7 rate it Buy, 6 Hold and 2 Sell. Targets range from $2.50 to $10. The latest change came on Aug 21, 2026, when Barclays raised its price target on GoodRx Holdings from $3 to $4 and kept an Underweight rating.

The Average Analyst Price Target for GoodRx Holdings is $5.79.

Price Target Range — 12 Quarters

Analyst Consensus — 15 Analysts

7Buy

6Hold

2Sell

Consensus RatingOutperform# Analysts15Avg. Consensus PT$5.79Upside to Avg. PT+64.0%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for GoodRx Holdings Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 21, 2026	Barclays	Glen Santangelo	PT Raise	Underweight	$3→$4
Aug 13, 2026	UBS	Kevin Caliendo	PT Raise	Neutral	$3→$4
Aug 11, 2026	Citigroup	Daniel Grosslight	PT Raise	Buy	$4→$5
Aug 11, 2026	TD Cowen	Charles Rhyee	PT Raise	Buy	$4→$5
Aug 7, 2026	Wells Fargo	Stan Berenshteyn	PT Raise	Overweight	$4→$5
May 14, 2026	Citigroup	Daniel Grosslight	PT Raise	Buy	$4→$4
May 11, 2026	TD Cowen	Charles Rhyee	PT Raise	Buy	$3→$4
Mar 4, 2026	Wells Fargo	Stan Berenshteyn	PT Cut	Overweight	$7→$4
Mar 3, 2026	Citigroup	Daniel Grosslight	PT Cut	Buy	$5→$4
Mar 2, 2026	Goldman Sachs	Eric Sheridan	PT Cut	Neutral	$4→$3
Feb 27, 2026	Mizuho	Steven Valiquette	PT Cut	Neutral	$4→$3
Feb 27, 2026	JP Morgan	Lisa Gill	Downgrade	Overweight→Neutral	—
Jan 22, 2026	Jefferies	Glen Santangelo	Downgrade	Buy→Hold	$5→$3
Jan 9, 2026	Citigroup	Daniel Grosslight	PT Cut	Buy	$5→$5
Dec 18, 2025	Morgan Stanley	Craig Hettenbach	PT Cut	Equal-Weight	$5→$4
Dec 9, 2025	Barclays	Glen Santangelo	Initiate	Underweight	$3
Nov 11, 2025	JP Morgan	Lisa Gill	PT Cut	Overweight	$6→$5
Nov 10, 2025	TD Cowen	Charles Rhyee	PT Cut	Buy	$7→$6
Nov 6, 2025	UBS	Kevin Caliendo	PT Cut	Neutral	$4→$4
Nov 6, 2025	Mizuho	Steven Valiquette	PT Cut	Neutral	$5→$4